Adicet Bio (LTS:0HX7) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Change In Receivables?

Adicet Bio's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Adicet Bio's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Adicet Bio's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Adicet Bio's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Adicet Bio's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Adicet Bio's liquidation value for the three months ended in Mar. 2024 was $213.30 Mil.

Adicet Bio Change In Receivables Historical Data

The historical data trend for Adicet Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Change In Receivables Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.03

0.19

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Adicet Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Adicet Bio (LTS:0HX7) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Adicet Bio's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Adicet Bio's accounts receivable are only considered to be worth 75% of book value:

Adicet Bio's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	247.589	-	34.291	+	0.75 * 0	+	0.5 * 0
=	213.30

Adicet Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (LTS:0HX7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (LTS:0HX7) Headlines

No Headlines